The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.

To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.

For additional information please review our Privacy Policy.


Optimizing CML Therapeutic Outcomes in the Era of Tyrosine Kinase Inhibitors


This presentation was selected by the American Society of Clinical Oncology® as an independent educational activity held in conjunction with an ASCO meeting. This presentation is not sponsored or endorsed by ASCO.

Optimizing CML Therapeutic Outcomes in the Era of Tyrosine Kinase Inhibitors


Welcome/Introductions
Speaker: Moshe Talpaz

Complete Cytogenic vs Major Molecular Response: Which is the Most Important Goal?
Speaker: Jerald P. Radich

Correlating Clinical Response with BCR-ABL Mutation Status
Speaker: Susan Branford

Case 2: Refractory CML
Speaker: Jorge E. Cortes

What's Next? The Role of Stem Cell Transplant and Integration of Novel Agents
Speaker: Moshe Talpaz





 
2318 Mill Road, Suite 800, Alexandria, VA 22314   |   phone: (571) 483-1300
© 2005-2009 American Society of Clinical Oncology (ASCO).  All rights reserved worldwide.